Doctors may soon be able to detect and monitor a patient’s cancer with a simple blood test, reducing or eliminating the need for more invasive procedures, according to Purdue University research.
W. Andy Tao, a professor of biochemistry and member of the Purdue University Center for Cancer Research and colleagues identified a series of proteins in blood plasma that, when elevated, signify that the patient has cancer. Their findings were published in the early edition of the Proceedings of the National Academy of Sciences.
Tao’s work was done with samples from breast cancer patients, but it is possible the method could work for any type of cancer and other types of diseases. The work relies on analysis of microvesicles and exosomes in blood plasma.
Protein phosphorylation, the addition of a phosphate group to a protein can lead to cancer cell formation. So phosphorylated proteins, known as phosphoproteins, have been seen as prime candidates for cancer biomarkers. Until now, however, scientists weren’t sure identification of phosphoproteins in blood was possible because the liver releases phosphatase into the bloodstream, which dephosphorylates proteins.
“There are so many types of cancer, even multiple forms for different types of cancer, that finding biomarkers has been discouraging,” Tao said. “This is definitely a breakthrough, showing the feasibility of using phosphoproteins in blood for detecting and monitoring diseases.”
Tao and his colleagues found nearly 2,400 phosphoproteins in a blood sample and identified 144 that were significantly elevated in cancer patients. The study compared 1-milliliter blood samples from 30 breast cancer patients with six healthy controls.
The researchers used centrifuges to separate plasma from red blood cells, and high-speed and ultra-high-speed centrifuges to further separate microvesicles and exosomes. Those particles, which are released from cells and enter the bloodstream, may play a role in intercellular communication and are thought to be involved in metastasis, spreading cancer from one place to another in the body. They also encapsulate phosphoproteins, which Tao’s team identified using mass spectrometry.
“Extracellular vesicles, which include exosomes and microvesicles, are membrane-encapsulated. They are stable, which is important,” Tao said. “The samples we used were 5 years old, and we were still able to identify phosphoproteins, suggesting this is a viable method for identifying disease biomarkers.”
A simple blood test for cancer would be far less invasive than scopes or biopsies that remove tissue. A doctor could also regularly test a cancer patient’s blood to understand the effectiveness of treatment and monitor patients after treatment to see if the cancer is returning.
“There is currently almost no way to monitor patients after treatment,” Tao said. “Doctors have to wait until cancer comes back.”
Timothy Ratliff, director of the Purdue University Center for Cancer Research, said the findings are promising for early detection of cancer.
“The vesicles and exosomes are present and released by all cancers, so it could be that there are general patterns for cancer tissues, but it’s more likely that Andy will develop patterns associated with different cancers. It’s really exciting,” Ratliff said. “Early detection in cancer is key and has been shown to clearly reduce the death rate associated with the disease.”
Tao plans to analyze increased levels of phosphoproteins in various types of cancer to determine whether there are patterns that would signify the type of cancer a patient has. His company, Tymora Analytical, is also developing technology that would allow doctors to insert blood samples onto a cartridge and analyze phosphoproteins present, eliminating the need for ultra-high-speed centrifuges that aren’t practical in clinical settings.
[osd_subscribe categories=’cancer-blood-test’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “CANCER BLOOD TEST”‘]
Receive an email update when we add a new CANCER BLOOD TEST article.
The Latest on: Cancer blood test
[google_news title=”” keyword=”cancer blood test” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cancer blood test
- New blood test may quickly diagnose this fatal inflammatory diseaseon February 25, 2024 at 7:22 pm
To verify the test, researchers compared blood samples from 386 people, which included patients with sarcoidosis, patients with tuberculosis, patients with lung cancer, and healthy individuals. The ...
- Cancer returns for Manchester leukaemia patient Dillanon February 25, 2024 at 4:25 am
Dillan was diagnosed with leukaemia at the age of one during the first coronavirus lockdown in May 2020. His mother Amy, from Manchester, said recent test results showed cancer. In an online post, she ...
- Cancer returns for leukaemia patient Dillanon February 25, 2024 at 4:24 am
The mother of a five-year-old boy who received a bone marrow transplant after an appeal says he has relapsed and his chance of a cure is "very small".Dillan was diagnosed with leukaemia at the age of ...
- There's One Way To Check For Ovarian Cancer That Nobody Talks About – Here's Whyon February 25, 2024 at 4:09 am
However, a controversial blood test exists that can measure the cancer antigen 125 (CA125) that can potentially detect ovarian cancer in its early stages. So why is it that ovarian cancer so difficult ...
- Can blood tests detect mouth and throat cancers?on February 15, 2024 at 6:05 pm
Blood tests cannot detect throat cancer. However, they can help indicate a person’s overall health. Doctors may use them to determine whether a person is a suitable candidate for certain types ...
- Can a blood test diagnose melanoma?on February 15, 2024 at 4:00 pm
Melanoma is an aggressive form of skin cancer that is easier to treat when doctors diagnose it early. Doctors use various tests to diagnose melanoma, and blood tests are one of the tools that ...
- Roche leads Freenome's $254M funding round for cancer-detecting blood testson February 15, 2024 at 6:27 am
Roche has participated in all of Freenome’s previous fundraising sessions and was also responsible for the $290 million contribution at the start of 2022 that brought Freenome’s total past the $1 ...
- Freenome raises $254M for blood test for early detection of canceron February 15, 2024 at 5:28 am
Cancer 'liquid biopsy' test developer Freenome ups its fundraising take to $1.3 billion with investment from Roche, Quest and others ...
- Cancer test firm Freenome raises $254 million in fresh fundingon February 15, 2024 at 5:03 am
Blood test developer Freenome said on Thursday it has raised $254 million in a new funding round led by Swiss drugmaker Roche, to develop tests that can potentially detect multiple early-stage cancers ...
via Bing News